BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 37850692)

  • 1. A TGF-β signaling-related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response.
    Duan WW; Yang LT; Liu J; Dai ZY; Wang ZY; Zhang H; Zhang X; Liang XS; Luo P; Zhang J; Liu ZQ; Zhang N; Mo HY; Qu CR; Xia ZW; Cheng Q
    CNS Neurosci Ther; 2024 Apr; 30(4):e14489. PubMed ID: 37850692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value and immune landscaps of m6A/m5C-related lncRNAs signature in the low grade glioma.
    Li R; Chen H; Li C; Qi Y; Zhao K; Wang J; You C; Huang H
    BMC Bioinformatics; 2023 Jul; 24(1):274. PubMed ID: 37403043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative analysis of a novel super-enhancer-associated lncRNA prognostic signature and identifying LINC00945 in aggravating glioma progression.
    Yang Z; Zheng Y; Wu H; Xie H; Zhao J; Chen Z; Li L; Yue X; Zhao B; Bian E
    Hum Genomics; 2023 Mar; 17(1):33. PubMed ID: 37004060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analyses indicated the association between m6A related long non-coding RNAs and various pathways in glioma.
    Chen Z; Zhang W; Yan Z; Zhang M
    Cancer Med; 2023 Jan; 12(1):760-788. PubMed ID: 35668574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of oxidative stress-related lncRNA signatures in glioma reveals the discrepancy of prognostic and immune infiltration.
    Shi Z; Wu Y; Zhuo Q; Zuo Y; Lin J; Shi H; Zhou H; Xu Z
    Sci Rep; 2023 May; 13(1):7731. PubMed ID: 37173373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
    Xu S; Tang L; Liu Z; Luo C; Cheng Q
    Front Immunol; 2021; 12():731048. PubMed ID: 34659218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.
    Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z
    Front Immunol; 2022; 13():951455. PubMed ID: 36189298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
    Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
    Front Immunol; 2022; 13():891175. PubMed ID: 35990668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel lncRNA Panel Related to Ferroptosis, Tumor Progression, and Microenvironment is a Robust Prognostic Indicator for Glioma Patients.
    He Y; Ye Y; Tian W; Qiu H
    Front Cell Dev Biol; 2021; 9():788451. PubMed ID: 34950662
    [No Abstract]   [Full Text] [Related]  

  • 10. A Novel Aging-Related Prognostic lncRNA Signature Correlated with Immune Cell Infiltration and Response to Immunotherapy in Breast Cancer.
    Liu Z; Ren C; Cai J; Yin B; Yuan J; Ding R; Ming W; Sun Y; Li Y
    Molecules; 2023 Apr; 28(8):. PubMed ID: 37110517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a TGF-β signaling-related gene signature for prediction of immunotherapy and targeted therapy for lung adenocarcinoma.
    Yu Q; Zhao L; Yan XX; Li Y; Chen XY; Hu XH; Bu Q; Lv XP
    World J Surg Oncol; 2022 Jun; 20(1):183. PubMed ID: 35668494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma.
    Maimaiti A; Wang X; Pei Y; Nuermaimaiti N; Tuersunniyazi A; Abula Y; Feng Z; Jiang L; Shi X; Kasimu M
    Aging (Albany NY); 2021 Jun; 13(11):15164-15192. PubMed ID: 34081618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA profile study reveals four-lncRNA signature associated with the prognosis of patients with anaplastic gliomas.
    Wang W; Yang F; Zhang L; Chen J; Zhao Z; Wang H; Wu F; Liang T; Yan X; Li J; Lan Q; Wang J; Zhao J
    Oncotarget; 2016 Nov; 7(47):77225-77236. PubMed ID: 27764782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA-ATB promotes TGF-β-induced glioma cells invasion through NF-κB and P38/MAPK pathway.
    Tang F; Wang H; Chen E; Bian E; Xu Y; Ji X; Yang Z; Hua X; Zhang Y; Zhao B
    J Cell Physiol; 2019 Dec; 234(12):23302-23314. PubMed ID: 31140621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methylation-related lncRNAs predict prognosis and immunotherapy response in gastric cancer.
    Guo X; Wang Y; Zha L; Li H; Qian K
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):14745-14760. PubMed ID: 37592033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Immune-Related lncRNA Prognostic Signature and Molecular Subtypes for Glioblastoma.
    Yu W; Ma Y; Hou W; Wang F; Cheng W; Qiu F; Wu P; Zhang G
    Front Immunol; 2021; 12():706936. PubMed ID: 34899682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long non-coding RNA AGAP2-AS1 promotes the proliferation of glioma cells by sponging miR-15a/b-5p to upregulate the expression of HDGF and activating Wnt/β-catenin signaling pathway.
    Zheng Y; Lu S; Xu Y; Zheng J
    Int J Biol Macromol; 2019 May; 128():521-530. PubMed ID: 30684575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel endoplasmic reticulum stress-related lncRNA signature for prognosis prediction and immune response evaluation in Stomach adenocarcinoma.
    Song Z; Su M; Li X; Xie J; Han F; Yao J
    BMC Gastroenterol; 2023 Dec; 23(1):432. PubMed ID: 38066437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
    Wang S; Bai H; Fei S; Miao B
    Biochem Genet; 2023 Oct; ():. PubMed ID: 37898914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
    Liu Y; Jiang J
    Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.